<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1709245928
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rufzel
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RUFINAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        460
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        665.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AF03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rufzel contains a medicine called rufinamide. It belongs to a group of medicines called antiepileptics, which are used to treat epilepsy (a condition where someone has seizures or fits). Rufzel is used with other medicines to treat seizures associated with Lennox-Gastaut syndrome in adults, adolescents and children from 1 year of age. Lennox-Gastaut syndrome is the name given to a group of severe epilepsies in which you may experience repeated seizures of various types. Rufina has been given to you by your doctor to reduce the number of your seizures or fits.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Rufzel : - if you are allergic to rufinamide or triazole derivatives or any of the other ingredients of Rufzel listed in section 6).<br />Warnings and precautions<br />Talk to your doctor or pharmacist if:</p><p>you have Congenital Short QT Syndrome or a family history of such a syndrome (electrical disturbance of the heart), as taking rufinamide could make it worse.<br />- you suffer from liver problems. There is limited information on the use of rufinamide in this group, so the dose of your medicine may need to be increased more slowly. If your liver disease is severe the<br />doctor may decide Rufzel is not recommended for you. - you get a skin rash or fever. These could be signs of an allergic reaction. See the doctor immediately as very occasionally this may become serious.<br />- you suffer an increase in the number or severity or duration of your seizures, you should contact the doctor immediately if this happens.<br />- you experience difficulty walking, abnormal movement, dizziness or sleepiness inform the doctor, if any of these happen.<br />- if you take this medicine and have thoughts of harming or killing yourself at any time, contact your<br />doctor or go to a hospital straight away (see section 4). Consult the doctor, even if these events occurred at any time in the past. Children Rufina should not be given to children younger than 1 year of age since there is not enough information on its use in this age group. Other medicines and Rufzel Tell the doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. If you are taking the following medicines: phenobarbital, fosphenytoin, phenytoin or primidone, you may need to be carefully monitored for two weeks at the start of, or after the end of treatment with rufinamide, or after any marked change in the dose. A change in the dose of the other medicines may be needed as they may become slightly less effective when given with rufinamide. Antiepileptic medicines and Rufzel If the doctor prescribes or recommends an additional treatment for epilepsy (e.g., valproate) you must tell the doctor you are taking Rufzel as the dose may need adjusting. Adults and children taking valproate at the same time as rufinamide will result in high levels of rufinamide in the blood. Tell your doctor if you are taking valproate as the dose of Rufzel may need to be reduced by your doctor. Tell the doctor if you are taking hormonal/oral contraceptives, e.g., &ldquo;The pill&rdquo;. Rufzel may make the pill not effective at preventing pregnancy. Therefore, it is recommended that you use an additional safe and effective contraceptive method (such as a barrier method, e.g., condoms) when taking Rufzel . Tell the doctor if you are taking the blood thinner &ndash; warfarin. The doctor may need to adjust the dose.</p><p>Tell the doctor if you are taking digoxin (a medicine used to treat heart conditions). The doctor may need to adjust the dose. Rufzel with food and drink See section 3 &ndash; &lsquo;How to use Rufzel &rsquo; for advice on taking Rufzel with food and drink. Pregnancy, breast-feeding and fertility If you are pregnant, or think you might be pregnant, or are planning to get pregnant, ask the doctor or pharmacist for advice before taking Rufzel . You must only take Rufzel during your pregnancy if the doctor tells you to. You are advised not to breast-feed while taking Rufzel , as it is not known if rufinamide will be present in breast milk. If you are a woman of childbearing age, you must use contraceptive measures while taking Rufzel . Ask the doctor or pharmacist for advice before taking any medicine at the same time as Rufzel . Driving and using machines Rufzel may make you feel dizzy, drowsy and affect your vision, particularly at the beginning of treatment or after a dose increase. If this happens to you, do not drive or operate machinery. Rufzel contains sorbitol Patients with rare, hereditary problems of fructose intolerance should not take this medicine. Rufzel contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) These ingredients may cause allergic reactions (possibly delayed).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with the doctor or pharmacist if you are not sure. It may take a while to find the best dose of Rufzel for you. The dose will be calculated for you by the doctor and will depend on your age, weight and whether you are taking Rufina with another medicine called valproate. Children aged between 1 and 4 years of age The recommended starting dose is 10 mg (0.25 ml) for each kilogram of body weight, each day. Taken in two equal doses, half in the morning and the other half in the evening. The dose will be calculated for you by the doctor and may be increased by 10 mg (0.25 ml) for each kilogram of body weight, every third day. The maximum daily dose will depend on whether or not you are also taking valproate. Maximum daily dose not taking valproate is 45 mg (1.125 ml) for each kilogram of body weight, each day. Maximum daily dose taking valproate is 30 mg (0.75 ml) for each kilogram of body weight, each day.</p><p>Children 4 years of age or older weighing less than 30 kg The recommended starting dose is 200 mg (5 ml) a day. Taken in two equal doses, half in the morning and the other half in the evening. The dose will be calculated for you by the doctor and may be increased by 200 mg (5 ml) every third day. The maximum daily dose will depend on whether or not you are also taking valproate. Maximum daily dose not taking valproate is 1,000 mg (25 ml) each day. Maximum daily dose taking valproate is 600 mg (15 ml) each day. Adults, adolescents and children weighing 30 kg or over The recommended starting dose is 400 mg (10 ml) a day. Taken in two equal doses, half in the morning and the other half in the evening. The dose will be calculated for you by the doctor and may be increased by 400 mg (10 ml) every other day. The maximum daily dose will depend on whether or not you are also taking valproate. Maximum daily dose not taking valproate is no more than 3,200 mg (80 ml), depending on body weight. Maximum daily dose taking valproate is no more than 2,200 mg (55 ml), depending on body weight. Some patients may respond to lower doses and your doctor may adjust the dose depending on how you respond to the treatment. If you experience side effects, your doctor may increase the dose more slowly. Rufzel oral suspension must be taken twice every day, once in the morning and once in the evening. Rufzel should be taken with food. Method of administration For dosing, please use the syringe and adaptor provided. Instructions on how to use the syringe and adaptor are provided below:</p><p>1.Shake well before use.<br />2.Push down (1) and turn cap (2) to open bottle<br />3.Insert adaptor into the neck of the bottle until a tight seal is made<br />4.Push plunger of syringe completely down<br />5.Insert the syringe into the opening of the adaptor as far as possible.<br />6.Turn upside down and withdraw the prescribed amount of Rufzel from the bottle.<br />7.Turn upright and remove the syringe.<br />8.Leave the adaptor in place and replace cap on bottle.<br />9.After dose administration, separate barrel and plunger, and fully immerse both components in HOTsoapy water.<br />10.Immerse the barrel and plunger in water to remove any residual detergent, shake off excess water andleave components to air dry. Do not wipe dry the dispensers.<br />11.Do not clean and reuse the syringe after 40 uses, or if the markings on the syringe wash off.<br />Do not reduce the dose or stop this medicine unless the doctor tells you to.</p><p>If you take more Rufzel than you should If you may have taken more Rufzel than you should, tell the doctor or pharmacist immediately, or contact your nearest hospital casualty department, taking the medicine with you. If you forget to take Rufzel If you forget to take a dose, continue taking the medicine as normal. Do not take a double dose to make up for forgotten dose. If you miss taking more than one dose, seek advice from the doctor. If you stop taking Rufzel If the doctor advises stopping treatment, follow their instructions concerning the gradual reduction of Rufina in order to lower the risk of an increase in seizures. If you have any further questions on the use of this product, ask the doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Rufinamide can cause side effects, although not everybody gets them.<br />The following side effects can be very serious:<br />Rash and/or fever. These could be signs of an allergic reaction. If they happen to you tell your doctor or go to a hospital immediately:<br />Change in the types of seizures you experience/more frequent seizures which last a long time (called status epilepticus). Tell your doctor immediately.<br />A small number of people being treated with antiepileptics such as Rufinamide have had thoughts of harming or killing themselves. If at any time you have these thoughts contact your doctor immediately (see section 2).<br />You may experience the following side effects with this medicine. Tell the doctor if you have any of the following:<br />Very common (more than 1 in 10 patients) side effects of Rufinamide are:<br />Dizziness, headache, nausea, vomiting, sleepiness, fatigue.<br />Common (more than 1 in a 100 patients) side effects of Rufinamide are:<br />Problems associated with nerves including: difficulty walking, abnormal movement, convulsions/seizures, unusual eye movements, blurred vision, trembling.<br />Problems associated with the stomach including: stomach pain, constipation, indigestion, loose stools (diarrhoea), loss or change in appetite, weight loss.<br />Infections: ear infection, flu, nasal congestion, chest infection.<br />In addition, patients have experienced: anxiety, insomnia, nose bleeds, acne, rash, back pain, infrequent periods, bruising, head injury (as a result of accidental injury during a seizure).</p><p>Uncommon (between 1 in a 100 and 1 in a 1000 patients) side effects of Rufinamide are:<br />Allergic reactions and an increase in markers of liver function (hepatic enzyme increase).<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)<br />Reporting of suspected adverse reactions<br />&bull;Saudi Arabia:<br />oOther GCC States:<br />Please contact the relevant competent authority.<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />oFax: +966-11-205-7662<br />oCall NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />oToll free phone: 8002490000<br />oE-mail: npc.drug@sfda.gov.sa<br />oWebsite: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C.<br />&bull;Keep out of reach of children.<br />&bull;Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry<br />date refers to the last day of the month.<br />&bull;If you have any suspension left in the bottle more than 90 days after it was first opened, do not use it.<br />&bull;Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how<br />to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Rufzel containsThe active substance is Rufinamide USP. Each mL of suspension contains 40 mg of Rufinamide USP. The other ingredients are: Microcrystalline cellulose and Carboxymethylcellulose sodium, Simethicone Emulsion 30%, Poloxamer, Hydroxyethyl cellulose, Noncrystallizing Sorbitol solution 70%, Potassium Sorbate, Propylene glycol, Methylparaben, Propylparaben, Anhydrous Citric Acid, Orange 051941A and Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                White orange flavored suspension.
How supplied: Rufzel is Supplied in 460 mL in Amber PET Bottle PackContainer: Amber color PET bottle 16 oz with 24 mm NeckClosure: Child resistant plastic caps with Expanded PE wad, 24 mm Oral Dosing Syringe: 20 mL Polypropylene Oral Dosing Syringe With Adapter (2 no’s Syringes and 1 no. Adapter) (1 to 20mL Markings)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer&nbsp;<br />Saudi Amarox Industrial Company&nbsp;<br />Al Jamiah Street, Al Malaz District&nbsp;<br />Riyadh 12629. Saudi Arabia&nbsp;<br />Tel &amp; Fax: +966 11 226 8850&nbsp;<br />Manufacturer&nbsp;<br />Hetero Labs Limited Unit Ill - India&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October, 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>یحتوي روفزل على دواء یسمى روفینامید. ینتمي إلى مجموعة من الأدویة تسمى مضادات الصرع ، والتي تستخدم لعلاج الصرع (حالة<br />یصاب فیھا الشخص بنوبات صرع أو نوبات) .<br />یستخدم رو فزل مع أدویة أخرى لعلاج النوبات المصاحبة لمتلازمة لینوكس-غاستو لدى البالغین والمراھقین والأطفال من عمر سنة<br />واحدة. متلازمة لینوكس-غاستو ھو الاسم الذي یطلق على مجموعة من نوبات الصرع الشدید التي قد تتعرض فیھا لنوبات متكررة من<br />أنواع مختلف ة.<br />یتم أعطاك رو فزل من قبل طبیبك لتقلیل عدد النوبات أو النوبات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم روفزل معلق فمو ي<br />.( - إذا كنت تعاني من حساسیة تجاه روفینامید أو أي من المكونات الأخرى لھذا الدواء (المدرجة في القسم 6<br />التحذیرات والاحتیاطا ت<br />تحدث إلى طبیبك أو الصیدلي قبل تناول روفزل وذلك في الحالات التالیة :<br />الخلقیة القصیرة أو لدیك تاریخ عائلي لمثل ھذه المتلازمة (اضطراب كھربائي للقلب) ، حیث أن QT - إذا كان لدیك متلازمة<br />تناول رو فزل قد یزید الأمر سوءًا.<br />- إذا كنت تعاني من مشاكل في الكبد. ھناك معلومات محدودة عن استخدام روفینامید في ھذه المجموعة ، لذلك قد تحتاج إلى<br />زیادة جرعة الدواء بشكل أبطأ. إذا كان مرض الكبد لدیك شدیدًا ، فقد یقرر الطبیب أن روفزل غیر موصى بھ ل ك.<br />- إذا أصبت بطفح جلدي أو حمى. یمكن أن تكون ھذه علامات الحساسیة. راجع الطبیب فورًا لأن ذلك قد یصبح خطیرًا في<br />بعض الأحیان.<br />- إذا كنت تعاني من زیادة في عدد أو حدة أو مدّة نوبات الصرع لدیك ، یجب علیك الاتصال بالطبیب على الفور إذا حدث ذل ك.<br />- إذا واجھت صعوبة في المشي ، حركة غیر طبیعیة ، دوار أو نعاس ، أخبر الطبیب في حالة حدوث أي من ھذه الأعرا ض.</p><p>إذا كنت تتناول ھذا الدواء ولدیك أفكار لإیذاء نفسك أو قتل نفسك في أي وقت ، فاتصل بطبیبك أو اذھب إلى المستشفى على<br />. ( الفور (انظر القسم 4<br />استشر الطبیب حتى لو حدثت ھذه الأحداث في أي وقت في الماض ي.<br />الأطفال<br />لا ینبغي إعطاء روفزل للأطفال الذین تقل أعمارھم عن سنة واحدة لعدم وجود معلومات كافیة عن استخدامھ في ھذه الفئة العمریة.<br />الأدویة الأخرى وتناول روفزل معلق فمو ي<br />أخبر الطبیب أو الصیدلي إذا كنت تتناول أو تناولت مؤخرًا أي أدویة أخرى ، بما في ذلك الأدویة التي تم الحصول علیھا بدون وصفة<br />طبیة. إذا كنت تتناول الأدویة التالیة: فینوباربیتال ، فوسفینیتوین ، فینیتوین أو بریمیدون ، قد تحتاج إلى المراقبة الدقیقة لمدة أسبوعین في<br />بدایة العلاج باستخدا م رو فزل أو بعد انتھائھ ، أو بعد أي تغییر ملحوظ في الجرعة. قد تكون ھناك حاجة لتغییر جرعة الأدویة الأخرى<br />لأنھا قد تصبح أقل فعالیة قلیلا عند إعطائھا مع رو فزل .<br />تناول أدویة الصرع و روفزل<br />إذا وصف الطبیب أو أوصى بعلاج إضافي للصرع (على سبیل المثال ، فالبروات) یجب أن تخبر الطبیب بأنك تتناول روفزل لأن<br />الجرعة قد تحتاج إلى تعدیل.<br />البالغون والأطفال الذین یتناولون فالبروات في نفس الوقت مع روفزل سینتج عنھ مستویات عالیة من روفینامید في الدم. أخبر طبیبك إذا<br />كنت تتناول فالبروات لأن جرعة روفزل قد یحتاج إلى تخفیضھا من قبل طبیبك.<br />بلغي الطبیب إذا كنت تتناولین موانع حمل ھرمونیة / فمویة ، على سبیل المثال ، &quot;حبوب منع الحمل&quot;. قد یجعل روفزل حبوب منع الحمل<br />غیر فعالة في منع الحمل. لذلك ، یوصى باستخدام وسیلة إضافیة آمنة وفعالة لمنع الحمل (مثل الواقي الذكري) عند تناول روفزل .<br />أبلغ الطبیب إذا كنت تتناول أدویة منع تجلط الدم - وارفارین. قد یحتاج الطبیب إلى تعدیل الجرعة.<br />أبلغ الطبیب إذا كنت تتناول دیجوكسین (دواء یستعمل لعلاج أمراض القلب). قد یحتاج الطبیب إلى تعدیل الجرع ة.<br />تناول روفزل مع الطعام والشرا ب<br />انظر القسم 3 - &quot;كیفیة استخدام روفزلا &quot; للحصول على نصائح حول تناول روفزل مع الطعام والشرا ب.<br />الحمل والرضاعة والخصوب ة<br />إذا كنت حاملا ، أو تعتقدین أنك حامل ، أو تخططین للحمل ، استشیري الطبیب أو الصیدلي قبل تناول روفزل. یجب أن تأخذ رو فزل<br />أثناء الحمل فقط إذ ا أخبرك الطبیب بذلك.<br />یُنصح بعدم الإرضاع أثناء تناول روفزل ، حیث لا یُعرف ما إذا كان روفینامید موجودًا في حلیب الثدي.<br />إذا كنت امرأة في سن الإنجاب ، فیجب علیك استخدام وسائل منع الحمل أثناء تناول رو فزل . استشر الطبیب أو الصیدلي قبل تناول أي<br />دواء في نفس الوقت مع روفزل .<br />القیادة واستخدام الآلا ت<br />قد یجعلك روفزل تشعر بالدوار والنعاس ویؤثر على رؤیتك خاصة في بدایة العلاج أو بعد زیادة الجرعة. إذا حدث ھذا لك ، فلا تقود أو<br />تشغل الآلات.<br />یحتوي روفزل على سوربیتو ل<br />المرضى الذین یعانون من مشاكل وراثیة نادرة من عدم تحمل الفركتوز یجب علیھم عدم تناول ھذا الدواء.<br />(E وبروبیل باراھیدروكسي بنزوا ت( 216 (E یحتوي روفزل على میثیل باراھیدروكسي بنزوا ت ( 218<br />قد تسبب ھذه المكونات ردود فعل تحسسیة (ربما تتأخر) .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرص دائمًا على تناول ھذا الدواء تمامًا كما أخبرك طبیبك. علیك الإستیضاح من الطبیب أو الصیدلي إذا لم تكن واثقا.</p><p>قد یستغرق الأمر بعض الوقت للعثور على أفضل جرعة من رو فزل المناسبة لك. سیتم احتساب الجرعة لك من قبل الطبیب وستعتمد<br />على عمرك ووزنك وما إذا كنت تتناول رو فزل مع دواء آخر یسمى فالبروات.<br />الأطفال الذین تتراوح أعمارھم بین 1 و 4 سنوات<br />جرعة البدء الموصى بھا ھي 10 ملجرام ( 0.25 مل) لكل كیلوغرام من وزن الجسم ، كل یوم. یتم تناولھا بجرعتین متساویتین ، نصف<br />في الصباح والنصف الآخر في المساء. سیتم احتساب الجرعة لك من قبل الطبیب ویمكن زیادتھا بمقدار 10 ملجرا م ( 0.25 مل) لكل<br />كیلوغرام من وزن الجسم ، كل یوم ثالث.<br />تعتمد الجرعة الیومیة القصوى على ما إذا كنت تتناول فالبروات أم لا. الحد الأقصى للجرعة الیومیة في الحالات التي لا تتناول فالبروات<br />ھو 45 ملجرام ( 1.125 مل) لكل كیلو غرام من وزن الجسم ، كل یوم. الحد الأقصى للجرعة الیومیة من تناول فالبروات ھو 30<br />ملجرام ( 0.75 مل) لكل كیلوغرام من وزن الجسم ، كل یوم.<br />الأطفال بعمر 4 سنوات أو أكبر ووزنھم أقل من 30 كجم<br />جرعة البدء الموصى بھا ھي 200 ملجرا م ( 5 مل) في الیوم. یتم تناولھا بجرعتین متساویتین ، نصف في الصباح والنصف الآخر في<br />المساء. سیحسب الطبیب الجرعة لك ویمكن زیادتھا بمقدار 200 ملجرام ( 5 مل) كل ثالث یو م.<br />تعتمد الجرعة الیومیة القصوى على ما إذا كنت تتناول فالبروات أم لا. الجرعة الیومیة القصوى في الحالات التي لا تتناول فالبروات ھي<br />1000 ملجرا م ( 25 مل) كل یوم. الحد الأقصى للجرعة الیومیة من تناول فالبروات ھو 600 ملجرا م ( 15 مل) كل یو م.<br />البالغون والمراھقون والأطفال بوزن 30 كغم أو أكثر<br />جرعة البدء الموصى بھا ھي 400 ملجرا م ( 10 مل) في الیوم. یتم تناولھا بجرعتین متساویتین ، نصف في الصباح والنصف الآخر في<br />المساء. سیتم احتساب الجرعة لك من قبل الطبیب ویمكن زیادتھا بمقدار 400 ملجرام ( 10 مل) كل یومین.<br />تعتمد الجرعة الیومیة القصوى على ما إذا كنت تتناول فالبروات أم لا. الجرعة الیومیة القصوى للمرضى اللذین لا ی تناولون فالبروات لا<br />تزید عن 3200 ملجرا م ( 80 مل) ، حسب وزن الجسم. الحد الأقصى للجرعة الیومیة من تناول فالبروات لا یزید عن 2200 ملجرا م<br />55 مل) ، حسب وزن الجس م. )<br />قد یستجیب بعض المرضى لجرعات أقل وقد یقوم طبیبك بتعدیل الجرعة اعتمادًا على كیفیة استجابتك للعلاج.<br />إذا كنت تعاني من آثار جانبیة ، فقد یقوم طبیبك بزیادة الجرعة بشكل أبطأ.<br />یجب تناو ل رو فزل المعلق مرتین یومیاً ، مرة في الصباح ومرة في المساء. یجب أن یتم تناو ل رو فزل مع الطعام.<br />طریقة التناو ل<br />لتناول الجرعات ، یرجى استخدام المحقنة والمحول المرفقین.<br />فیما یلي إرشادات حول كیفیة استخدام المحقنة والمحول :<br />12. اضغط على ( 1) وأدر الغطاء ( 2) لفتح الزجاج ة<br />3. أدخل المحول في عنق الزجاجة حتى یتم إحكام الغل ق<br />4. ادفع مكبس المحقنة لأسفل تمامًا<br />5 .أدخل المحقنة في فتحة المحول قدر الإمكان.<br />6 .اقلب الزجاج ة رأساً على عقب واسحب الكمیة الموصوفة من رو فزل من الزجاج ة.<br />7 .اقلب الزجاج ة وأزل المحقن ة.<br />8 .اترك المحول في مكانھ واستبدل الغطاء على الزجاجة.<br />9 .بعد تناول الجرعة ، افصل المحقنة والمكبس ، واغمس كلا المكونین بالكامل في الماء الساخن والصابون.<br />10 .اغمر المحقنة والمكبس في الماء لإزالة أي منظف متبقي ، وتخلص من الماء الزائد واترك المكونات لتجف في الھواء. لا تمسح<br />العبوات الجافة.<br />11 .لا تقم بتنظیف المحقنة وإعادة استخدامھا بعد 40 استخدامًا ، أو إذا تم غسل العلامات الموجودة على المحقنة. لا تقلل الجرعة أو<br />توقف ھذا الدواء إلا إذا أخبرك الطبیب بذلك.<br />تناول جرعة زائدة من روفزل معلق فمو ي<br />إذا كنت قد تناولت جرعة زائدة من روفزل ، أخبر الطبیب أو الصیدلي على الفور ، أو اتصل بأقرب قسم إصابة في المستشفى ،<br />واصطحب الدواء معك.<br />إذا نسیت أن تتناو ل رو فزل معلق فمو ي<br />إذا نسیت تناول جرعة ، فاستمر في تناول الدواء كالمعتاد. لا تتناو ل جرعة مضاعفة لتعویض الجرعة المنسیة. إذا فاتتك تناول أكثر من<br />جرعة واحدة ، فاطلب المشورة من الطبیب.<br />التوقف عن تتناو ل رو فزل معلق فمو ي<br />إذا نصح الطبیب بالتوقف عن العلاج ، فاتبع تعلیماتھ الخاصة بالتخفیض التدریجي ل روفزل من أجل تقلیل مخاطر زیادة النوبا ت.<br />إذا كانت لدیك أسئلة أخرى حول استخدام ھذا المنتج ، فاسأل الطبیب أو الصیدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جمیع الأدویة ، یمكن أن یتسبب رو فزل في حدوث آثار جانبیة ، على الرغم من عدم حدوثھا للجمیع. یمكن أن تكون الآثار الجانبیة<br />التالیة خطیرة للغای ة:<br />طفح جلدي و / أو حمى. یمكن أن تكون ھذه علامات الحساسیة. إذا حدث لك ذلك ، فأخبر طبیبك أو توجھ إلى المستشفى على الفو ر:<br />تغییر في أنواع النوبات التي تواجھھا / نوبات متكررة تستمر لفترة طویلة (تسمى الحالة الصرعیة). أخبر طبیبك على الفور .<br />كان لدى عدد قلیل من الأشخاص الذین یعالجون بمضادات الصرع مثل روفزل أفكارًا لإیذاء أنفسھم أو الانتحار. إذا راودتك ھذه الأفكار<br />. ( في أي وقت ، فاتصل بطبیبك على الفور (انظر القسم 2<br />قد تواجھ الآثار الجانبیة التالیة مع ھذا الدواء. أخبر الطبیب إذا كان لدیك أي مما یلي:<br />الأعراض الجانبیة الشائعة جداً (أكثر من 1 من كل 10 مرضى) لاستخدام روفزل ھي: دوار ، صداع ، غثیان ، قيء ، نعاس ، إرھاق.<br />الآثار الجانبیة الشائعة (أكثر من 1 من كل 100 مریض) لاستخدام رو فزل ھي:<br />المشاكل المرتبطة بالأعصاب بما في ذلك: صعوبة المشي ، والحركة غیر الطبیعیة ، والتشنجات / النوبات ، وحركات العین غیر العادیة<br />، وعدم وضوح الرؤیة ، والارتعاش.<br />المشاكل المصاحبة للمعدة بما في ذلك: آلام في المعدة ، إمساك ، عسر ھضم ، براز رخو (إسھال) ، فقدان أو تغیر في الشھیة ، فقدان<br />الوزن.<br />الالتھابات: التھاب الاذن ، انفلونزا ، احتقان بالأنف ، التھاب في الصدر.</p><p>بالإضافة إلى ذلك ، عانى المرضى من: القلق ، والأرق ، ونزیف الأنف ، وحب الشباب ، والطفح الجلدي ، وآلام الظھر ، وعدم انتظام<br />الطمث ، وكدمات ، وإصابة في الرأس (نتیجة إصابة عرضیة أثناء النوبة) .<br />الآثار الجانبیة غیر الشائع ة (بین 1 في 100 و 1 من كل 1000 مریض) الآثار الجانبیة ل روفزل : تفاعلات تحسسیة وزیادة في<br />مؤشرات وظائف الكبد (زیادة إنزیم الكبد) .<br />الإبلا غ عن الأعرا ض الجانبی ة:<br />إن كان لدیك أعرا ض جانبیة أ و لاحظت أعرا ض جانبیة غیر مذكورة في ھذه النشرة ، فضلاً ابلغ الطبیب أوالصیدل ي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><br />&bull; یحفظ في درجة حرارة أقل من 30 درجة مئویة.<br />&bull; احفظ ھذا الدواء بعیدًا عن رؤیة ومتناول أیدي الأطفال .<br />یشیر تاریخ انتھاء الصلاحیة إلى الیوم .EXP &bull; لا تستخدم ھذا الدواء بعد تاریخ انتھاء الصلاحیة المذكور على العبوة بعد<br />الأخیر من الشھر .<br />&bull; إذا بقي لدیك أي معلق في الزجاجة لأكثر من 90 یومًا بعد فتحھا لأول مرة ، فلا تستخدمھ.<br />&bull; لا تتخلص من الأدویة في میاه الصرف الصحي أو النفایات المنزلیة. اسأل الصیدلي عن كیفیة التخلص من الأدویة التي لم تعد<br />بحاجة إلیھا. ستساعد ھذه الإجراءات في حمایة البیئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة روفینامید المتوافق مع دستور الأدویة الأمریكي.<br />یحتوي كل مل من المعلق على 40 ملجرا م من روفینامید المتوافق مع دستور الأدویة الأمریكي.<br />الصواغات الأخرى ھي: السلیلوز دقیق التبلور وكاربوكسي میثیل سلولوز الصودیوم ، مستحلب سیمیثیكون 30 ٪ ، بولوكسامیر ،<br />ھیدروكسي إیثیل السلیلوز ، محلول سوربیتول غیر متبلور 70 ٪ ، سوربات البوتاسیوم ، بروبیلین جلیكول ، میثیل بارابین ، بروبیل<br />051941 والماء النقي. A بارابین ، حمض الستریك اللامائي ، ونكھة البرتقال</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">ما ھو شكل روفزل معلق فموي ؟<br />معلق أبیض بنكھة البرتقا ل.<br />كیفیة توفیر روفزل معلق فموي ؟<br />یتوافر رو فزل معلق فمو ي بسعة 460 مل في عبوة معتمة من مادة البولي إیثیلین تیریفثالات : زجاجة من مادة البولي إیثیلین تیریفثالات<br />ممتدة ، 24 مم PE ذات اللون الكھرماني 16 أونصة مع غطاء 24 مم: أغطیة بلاستیكیة مقاومة للأطفال مع حشو ة<br />محقنة الجرعات عن طریق الفم: 20 مل من مادة البولي بروبیلین عن طریق الفم محقنة مع محول ( 2 محاقن و محول) (مدرجة من 1<br />إلى 20 مل علامات )</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>صاحب حق التسویق :<br />شركة اماروكس السعودیة الصناعیة<br />شارع الجامع ة ، حي الملز<br />الریاض 12629 ، المملكة العربیة السعودیة<br />+966 11 226 ھاتف و فاكس: 8850<br />المصنع<br />شركة ھتیرو لاب المحدودة، الوحدة ألثالثة ، الھند.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة ھذ ه النشرة في اكتوبر 2023 , نسخة 1
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rufzel (Rufinamide Oral Suspension 40mg/mL)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rufzel (Rufinamide Oral Suspension 40mg/mL)
Each mL of suspension contains 40 mg of Rufinamide USP.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rufzel (Rufinamide Oral Suspension 40mg/mL)
White orange flavored suspension.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rufzel is indicated as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 1 year of age and older.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Rufinamide should be initiated by a physician specialised in paediatrics or neurology with experience in the treatment of epilepsy.<br />Rufinamide oral suspension and Rufinamide film-coated tablets may be interchanged at equal doses. Patients should be monitored during the switch over period.<br />Posology<br />Use in children from 1 year to less than 4 years of age<br />Patients not receiving valproate:<br />Treatment should be initiated at a dose of 10 mg/kg/day (0.25 ml/kg/day) administered in two equally divided doses separated by approximately 12 hours. According to clinical response and tolerability, the dose may be increased by up to 10 mg/kg/day (0.25 ml/kg/day) every third day to a target dose of 45 mg/kg/day (1.125 ml/kg/day) administered in two equally divided doses separated by approximately 12 hours. For this patient population, the maximum recommended dose is 45 mg/kg/day (1.125 ml/kg/day).Module-1<br />Patients receiving valproate:<br />As valproate significantly decreases clearance of rufinamide, a lower maximum dose of Rufina is recommended for patients being co-administered valproate. Treatment should be initiated at a dose of 10 mg/kg/day (0.25 ml/kg/day) administered in two equally divided doses separated by approximately 12 hours. According to clinical response and tolerability, the dose may be increased by up to 10 mg/kg/day (0.25 ml/kg/day) every third day to a target dose of 30 mg/kg/day (0.75 ml/kg/day) administered in two equally divided doses separated by approximately 12 hours. For this patient population, the maximum recommended dose is 30 mg/kg/day (0.75 ml/kg/day).<br />If the recommended calculated dose of Rufinamide is not achievable, the dose should be given to the nearest 0.5 ml of rufinamide.<br />Use in children 4 years of age or older and less than 30 kg<br />Patients &lt; 30 kg not receiving valproate:<br />Treatment should be initiated at a daily dose of 200 mg (5 ml dosing suspension given as two 2.5 ml doses, one in the morning and one in the evening). According to clinical response and tolerability, the dose may be increased by 200 mg/day increments, as frequently as every third day, up to a maximum recommended dose of 1,000 mg/day (25 ml/day).<br />Doses of up to 3,600 mg/day (90 ml/day) have been studied in a limited number of patients.<br />Patients &lt; 30 kg also receiving valproate:<br />As valproate significantly decreases clearance of rufinamide, a lower maximum dose of Rufinamide is recommended for patients &lt; 30 kg being co-administered valproate. Treatment should be initiated at a daily dose of 200 mg. According to clinical response and tolerability, after a minimum of 2 days the dose may be increased by 200 mg/day, to the maximum recommended dose of 600 mg/day (15 ml/day).<br />Use in adults, adolescents and children 4 years of age or older of 30 kg or over<br />Patients &gt; 30 kg not receiving valproate:<br />Treatment should be initiated at a daily dose of 400 mg (10 ml dosing suspension given as two 5 ml doses). According to clinical response and tolerability, the dose may be increased by 400</p><p>mg/day increments, as frequently as every other day, up to a maximum recommended dose as indicated in the table below.<br />Weight range<br />30.0 &ndash; 50.0 kg<br />50.1 &ndash; 70.0 kg<br />&ge;70.1 kg<br />Maximum recommended dose<br />1,800 mg/day or<br />45 ml/day<br />2,400 mg/day or<br />60 ml/day<br />3,200 mg/day or<br />80 ml/day<br />Doses of up to 4,000 mg/day (100 ml/day) in the 30 -50 kg range or 4,800 mg/day (120 ml/day) in the over 50 kg category have been studied in a limited number of patients.<br />Patients &gt; 30 kg also receiving valproate:<br />Treatment should be initiated at a daily dose of 400 mg (10 ml dosing suspension given as two 5 ml doses). According to clinical response and tolerability, the dose may be increased by 400 mg/day increments, as frequently as every other day, up to a maximum recommended dose as indicated in the table below.<br />Weight range<br />30.0 &ndash; 50.0 kg<br />50.1 &ndash; 70.0 kg<br />&ge;70.1 kg<br />Maximum recommended dose<br />1,200 mg/day or<br />30 ml/day<br />1,600 mg/day or<br />40 ml/day<br />2,200 mg/day or<br />55 ml/day<br />Elderly<br />There is limited information on the use of rufinamide in older people. Since the pharmacokinetics of rufinamide are not altered in older people (see section 5.2), dosage adjustment is not required in patients over 65 years of age.<br />Renal impairment<br />A study in patients with severe renal impairment indicated that no dose adjustments are required for these patients (see section 5.2).</p><p>Hepatic impairment<br />Use in patients with hepatic impairment has not been studied. Caution and careful dose titration is recommended when treating patients with mild to moderate hepatic impairment. Use in patients with severe hepatic impairment is not recommended.<br />Discontinuation of rufinamide<br />When rufinamide treatment is to be discontinued, it should be withdrawn gradually. In clinical trials rufinamide discontinuation was achieved by reducing the dose by approximately 25% every two days (see section 4.4).<br />In the case of one or more missed doses, individualised clinical judgement is necessary.<br />Uncontrolled open-label studies suggest sustained long-term efficacy, although no controlled study has been conducted for longer than three months.<br />Paediatric population<br />The safety and efficacy of rufinamide in new-born infants or infants and toddlers aged less than 1 year have not been established. No data are available (see section 5.2).<br />Method of administration<br />Rufinamide is for oral use.<br />The suspension should be taken twice daily in the morning and in the evening, in two equally divided doses.<br />Rufinamide should be administered with food (see section 5.2).<br />The oral suspension should be shaken vigorously before every administration. See section 6.6 for further details.<br />The prescribed dose of Rufinamide oral suspension can be administered via an enteral feeding tube. Follow the manufacturer&#39;s instructions for the feeding tube to administer the medicine. To ensure adequate dosing, after administration of the oral suspension, the enteral feeding tube must be flushed at least once with 1 ml of water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, triazole derivatives or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Status epilepticus<br />Status epilepticus cases have been observed during treatment with rufinamide in clinical development studies, whereas no such cases were observed with placebo. These events led to rufinamide discontinuation in 20% of the cases. If patients develop new seizure types and/or experience an increased frequency of status epilepticus that is different from the patient&#39;s baseline condition, then the benefit-risk ratio of the therapy should be reassessed.<br />Withdrawal of rufinamide<br />Rufinamide should be withdrawn gradually to reduce the possibility of seizures on withdrawal. In clinical studies discontinuation was achieved by reducing the dose by approximately 25% every two days. There are insufficient data on the withdrawal of concomitant antiepileptic medicinal products once seizure control has been achieved with the addition of rufinamide.<br />Central Nervous System reactions<br />Rufinamide treatment has been associated with dizziness, somnolence, ataxia and gait disturbances, which could increase the occurrence of accidental falls in this population (see section 4.8). Patients and carers should exercise caution until they are familiar with the potential effects of this medicinal product.<br />Hypersensitivity reactions<br />Serious antiepileptic medicinal product hypersensitivity syndrome including DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) and Stevens-Johnson syndrome have occurred in association with rufinamide therapy. Signs and symptoms of this disorder were diverse; however, patients typically, although not exclusively, presented with fever and rash associated with other organ system involvement. Other associated manifestations included lymphadenopathy, liver function tests abnormalities, and haematuria. As the disorder is variable in its expression, other organ system signs and symptoms not noted here may occur. The antiepileptic drug (AED) hypersensitivity syndrome occurred in close temporal association to the initiation of rufinamide therapy and in the paediatric population. If this reaction is suspected, rufinamide should be discontinued and alternative treatment started. All patients who develop a rash while taking rufinamide must be closely monitored.</p><p>QT shortening<br />In a thorough QT study, rufinamide produced a decrease in QTc interval proportional to concentration. Although the underlying mechanism and safety relevance of this finding is not known, clinicians should use clinical judgment when assessing whether to prescribe rufinamide to patients at risk from further shortening their QTc duration (e.g., Congenital Short QT Syndrome or patients with a family history of such a syndrome).<br />Women of childbearing potential<br />Women of childbearing potential must use contraceptive measures during treatment with rufinamide. Physicians should try to ensure that appropriate contraception is used, and should use clinical judgement when assessing whether oral contraceptives, or the doses of the oral contraceptive components, are adequate, based on the individual patients clinical situation (see sections 4.5 and 4.6).<br />Parahydroxybenzoates<br />Rufinamide oral suspension contains parahydroxybenzoates which may cause allergic reactions (possibly delayed).<br />Sorbitol<br />Rufinamide oral suspension also contains sorbitol and, therefore, should not be administered to patients with rare hereditary problems of fructose intolerance.<br />Suicidal ideation<br />Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications. A meta-analysis of randomised placebo-controlled trials of anti-epileptic medicinal products has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for Rufinamide<br />Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Potential for other medicinal products to affect rufinamide<br />Other antiepileptic medicinal products<br />Rufinamide concentrations are not subject to clinically relevant changes on co-administration with known enzyme inducing antiepileptic medicinal products.<br />For patients on Rufinamide treatment who have administration of valproate initiated, significant increases in rufinamide plasma concentrations may occur. Therefore, consideration should be given to a dose reduction of Rufinamide in patients who are initiated on valproate therapy (see section 4.2).<br />The addition or withdrawal of these medicinal products or adjusting of the dose of these medicinal products during rufinamide therapy may require an adjustment in dosage of rufinamide (see section 4.2).<br />No significant changes in rufinamide concentration are observed following co-administration with lamotrigine, topiramate or benzodiazepines.<br />Potential for rufinamide to affect other medicinal products<br />Other antiepileptic medicinal products<br />The pharmacokinetic interactions between rufinamide and other antiepileptic medicinal products have been evaluated in patients with epilepsy, using population pharmacokinetic modelling. Rufinamide appears not to have a clinically relevant effect on carbamazepine, lamotrigine, phenobarbital, topiramate, phenytoin or valproate steady state concentrations.<br />Oral contraceptives<br />Co-administration of rufinamide 800 mg twice daily and a combined oral contraceptive (ethinyloestradiol 35 &mu;g and norethindrone 1 mg) for 14 days resulted in a mean decrease in the ethinyl estradiol AUC0-24 of 22% and in norethindrone AUC0-24 of 14%. Studies with other oral or implant contraceptives have not been conducted. Women of child-bearing potential using hormonal contraceptives are advised&nbsp;Cytochrome P450 enzymes<br />Rufinamide is metabolised by hydrolysis, and is not metabolised to any notable degree by cytochrome P450 enzymes. Furthermore, rufinamide does not inhibit the activity of cytochrome P450 enzymes (see section 5.2). Thus, clinically significant interactions mediated through inhibition of cytochrome P450 system by rufinamide are unlikely to occur. Rufinamide has been shown to induce the cytochrome P450 enzyme CYP3A4 and may therefore reduce the plasma concentrations of substances which are metabolised by this enzyme. The effect was modest to moderate. The mean CYP3A4 activity, assessed as clearance of triazolam, was increased by 55% after 11 days of treatment with rufinamide 400 mg twice daily. The exposure of triazolam was reduced by 36%. Higher rufinamide doses may result in a more pronounced induction. It may not be excluded that rufinamide may also decrease the exposure of substances metabolised by other enzymes, or transported by transport proteins such as P-glycoprotein.<br />It is recommended that patients treated with substances that are metabolised by the CYP3A4 enzyme system are to be carefully monitored for two weeks at the start of, or after the end of treatment with rufinamide, or after any marked change in the dose. A dose adjustment of the concomitantly administered medicinal product may need to be considered. These recommendations should also be considered when rufinamide is used concomitantly with substances with a narrow therapeutic window such as warfarin and digoxin.<br />A specific interaction study in healthy subjects revealed no influence of rufinamide at a dose of 400 mg twice daily on the pharmacokinetics of olanzapine, a CYP1A2 substrate.<br />No data on the interaction of rufinamide with alcohol are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Risk related to epilepsy and antiepileptic medicinal products in general:<br />It has been shown that in the offspring of women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3% in the general population. In the treated population, an increase in malformations has been noted with polytherapy; however, the extent to which the treatment and/or the illness is responsible has not been elucidated.&nbsp;Moreover, effective antiepileptic therapy should not be interrupted abruptly, since the aggravation of the illness is detrimental to both the mother and the foetus. AED treatment during pregnancy should be carefully discussed with the treating physician.<br />Risk related to rufinamide:<br />Studies in animals revealed no teratogenic effect, but foetotoxicity in the presence of maternal toxicity was observed (see section 5.3). The potential risk for humans is unknown.<br />For rufinamide, no clinical data on exposed pregnancies are available.<br />Taking these data into consideration, rufinamide should not be used during pregnancy, or in women of childbearing age not using contraceptive measures, unless clearly necessary.<br />Women of childbearing potential must use contraceptive measures during treatment with rufinamide. Physicians should try to ensure that appropriate contraception is used, and should use clinical judgement when assessing whether oral contraceptives, or the doses of the oral contraceptive components, are adequate based on the individual patients clinical situation (see sections 4.4 and 4.5).<br />If women treated with rufinamide plan to become pregnant, the continued use of this product should be carefully weighed. During pregnancy, interruption of an effective antiepileptic can be detrimental to both the mother and the foetus if it results in aggravation of the illness.<br />Breast-feeding<br />It is not known if rufinamide is excreted in human breast milk. Due to the potential harmful effects for the breast-fed infant, breast-feeding should be avoided during maternal treatment with rufinamide.<br />Fertility<br />No data are available on the effects on fertility following treatment with rufinamide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rufinamide may cause dizziness, somnolence and blurred vision. Depending on the individual sensitivity, rufinamide may have a minor to major influence on the ability to drive and use machines. Patients must be advised to exercise caution during activities requiring a high degree of alertness, e.g., driving or operating machinery.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The clinical development program has included over 1,900 patients, with different types of epilepsy, exposed to rufinamide. The most commonly reported adverse reactions overall were headache, dizziness, fatigue, and somnolence. The most common adverse reactions observed at a higher incidence than placebo in patients with Lennox-Gastaut syndrome were somnolence and vomiting. Adverse reactions were usually mild to moderate in severity. The discontinuation rate in Lennox-Gastaut syndrome due to adverse reactions was 8.2% for patients receiving rufinamide and 0% for patients receiving placebo. The most common adverse reactions resulting in discontinuation from the rufinamide treatment group were rash and vomiting.<br />Tabulated list of adverse reactions<br />Adverse reactions reported with an incidence greater than placebo, during the Lennox-Gastaut syndrome double-blind studies or in the overall rufinamide-exposed population, are listed in the table below by MedDRA preferred term, system organ class and by frequency.<br />Frequencies are defined as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000).<br />System Organ Class<br />Very Common<br />Common<br />Uncommon<br />Rare<br />Infections and infestations<br />Pneumonia<br />Influenza<br />Nasopharyngitis<br />Ear infection<br />Sinusitis<br />Rhinitis<br />Immune system disorders<br />Hypersensitivity*<br />Metabolism and<br />Anorexia</p><p>nutrition disorders<br />Eating disorder<br />Decreased appetite<br />Psychiatric disorders<br />Anxiety<br />Insomnia<br />Nervous system disorders<br />Somnolence*<br />Headache<br />Dizziness*<br />Status epilepticus*<br />Convulsion<br />Coordination Abnormal*<br />Nystagmus<br />Psychomotor hyperactivity<br />Tremor<br />Eye Disorders<br />Diplopia<br />Vision blurred<br />Ear and Labyrinth disorders<br />Vertigo<br />Respiratory, thoracic and mediastinal disorders<br />Epistaxis<br />Gastrointestinal disorders<br />Nausea<br />Vomiting<br />Abdominal pain upper<br />Constipation<br />Dyspepsia<br />Diarrhoea<br />Hepatobiliary disorders<br />Hepatic enzyme increase<br />Skin and<br />Rash*</p><p>subcutaneous tissue disorders<br />Acne<br />Musculoskeletal and connective tissue and bone disorders<br />Back pain<br />Reproductive system and breast disorders<br />Oligomenorrhoea<br />General disorders and administration site conditions<br />Fatigue<br />Gait disturbance*<br />Investigations<br />Weight decrease<br />Injury, poisoning and procedural complications<br />Head injury<br />Contusion<br />*Cross reference to section 4.4.<br />Additional information on special populations<br />Paediatric Population (age 1 to less than 4 years)<br />In a multicentre, open-label study comparing the addition of rufinamide to any other AED of the investigator&#39;s choice to the existing regimen of 1 to 3 AEDs in paediatric patients, 1 to less than 4 years of age with inadequately controlled LGS, 25 patients, of which 10 subjects were aged 1 to 2 years, were exposed to rufinamide as adjunctive therapy for 24 weeks at a dose of up to 45 mg/kg/day, in 2 divided doses. The most frequently reported TEAEs in the rufinamide treatment group (occurring in &ge; 10% of subjects) were upper respiratory tract infection and vomiting (28.0% each), pneumonia and somnolence (20.0% each), sinusitis, otitis media, diarrhoea, cough and pyrexia (16.0% each), and bronchitis, constipation, nasal congestion, rash, irritability and&nbsp;decreased appetite (12.0% each). The frequency, type and severity of these adverse reactions were similar to that in children 4 years of age and older, adolescents and adults. Age characterisation in patients less than 4 years was not identified in the limited safety database due to small number of patients in the study.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)<br />Reporting of suspected adverse reactions</p><p>&bull; Saudi Arabia:<br />o Other GCC States:<br />Please contact the relevant competent authority.<br /><br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis. There is no specific antidote for rufinamide. Treatment should be supportive and may include haemodialysis (see section 5.2).<br />Multiple dosing of 7,200 mg/day was associated with no major signs or symptoms.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antiepileptics, carboxamide derivatives; ATC code: N03AF03.<br />Mechanism of action<br />Rufinamide modulates the activity of sodium channels, prolonging their inactive state. Rufinamide is active in a range of animal models of epilepsy.<br />Clinical experience<br />Rufzel (rufinamide tablets) was administered in a double blind, placebo-controlled study, at doses of up to 45 mg/kg/day for 84 days, to 139 patients with inadequately controlled seizures associated with Lennox-Gastaut Syndrome (including both atypical absence seizures and drop attacks). Male and female patients (between 4 and 30 years of age) were eligible if they had a history of multiple seizure types, which had to include atypical absence seizures and drop attacks (i.e., tonic&ndash;atonic or astatic seizures); were being treated with 1 to 3 concomitant fixed dose antiepileptic medicinal products; a minimum of 90 seizures in the month before the 28-day baseline period; an EEG within 6 months of study entry demonstrating a pattern of slow spike-and-wave complexes (2.5 Hz); a weight of at least 18 kg; and a CT scan or MRI study confirming the absence of a progressive lesion. All seizures were classified according to the International League Against Epilepsy Revised Classification of Seizures. As it is difficult for caregivers to precisely separate tonic and atonic seizures, the international expert panel of child neurologists agreed to group these seizure types and call them tonic&ndash;atonic seizures or &ldquo;drop attacks&rdquo;. As such, drop attacks were used as one of the primary end points. A significant improvement was observed for all three primary variables: the percentage change in total seizure frequency per 28 days during the maintenance phase relative to baseline (-35.8% on Rufzel vs. &ndash;1.6% on placebo, p=0.0006), the number of tonic-atonic seizures (-42.9% on Rufzel vs. 2.2% on placebo, p=0.0002), and the seizure severity rating from the Global Evaluation performed by the parent/guardian at the end of the double-blind phase (much or very much improved in 32.2% on Rufzel vs. 14.5% on the placebo arm, p=0.0041).<br />Additionally, Rufzel (rufinamide oral suspension) was administered in a multicentre, open-label study comparing the addition of rufinamide to the addition of any other AED of the investigator&#39;s&nbsp;choice to the existing regimen of 1 to 3 AEDs in paediatric patients, 1 to less than 4 years of age with inadequately controlled LGS. In this study, 25 patients were exposed to rufinamide as adjunctive therapy for 24 weeks at a dose of up to 45 mg/kg/day, in 2 divided doses. A total of 12 patients received any-other AED at the investigator&#39;s discretion in the control arm. The study was mainly designed for safety and not adequately powered to show a difference with regards to the seizure efficacy variables. The adverse event profile was similar to that in children 4 years of age and older, adolescents, and adults. In addition, the study investigated the cognitive development, behaviour and language development of subjects treated with rufinamide compared to subjects receiving any-other-AED. The Least Square mean change of the Child Behaviour Checklist (CBCL) Total Problems score after 2 years of treatment were 53.75 for the any other AED group and 56.35 for the rufinamide group (LS mean difference [95% CI] +2.60 [-10.5,15.7]; p=0.6928), and the difference between treatments was -2.776 (95% CI: -13.3, 7.8, p=0.5939).<br />Population pharmacokinetic/pharmacodynamic modelling demonstrated that the reduction of total and tonic-atonic seizure frequencies, the improvement of the global evaluation of seizure severity and the increase in probability of reduction of seizure frequency were dependent on rufinamide concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Maximum plasma levels are reached approximately 6 hours after administration. Peak concentration (Cmax) and plasma AUC of rufinamide increase less than proportionally with doses in both fasted and fed healthy subjects and in patients, probably due to dose-limited absorption behaviour. After single doses, food increases the bioavailability (AUC) of rufinamide by approximately 34% and the peak plasma concentration by 56%.<br />Rufinamide oral suspension and Rufinamide film-coated tablets have been demonstrated to be bioequivalent.<br />Distribution<br />In in vitro studies, only a small fraction of rufinamide (34%) was bound to human serum proteins with albumin accounting for approximately 80% of this binding. This indicates minimal risk of&nbsp;&nbsp;drug-drug interactions by displacement from binding sites during concomitant administration of other substances. Rufinamide was evenly distributed between erythrocytes and plasma.<br />Biotransformation<br />Rufinamide is almost exclusively eliminated by metabolism. The main pathway of metabolism is hydrolysis of the carboxylamide group to the pharmacologically inactive acid derivative CGP 47292. Cytochrome P450-mediated metabolism is very minor. The formation of small amounts of glutathione conjugates cannot be completely excluded.<br />Rufinamide has demonstrated little or no significant capacity in vitro to act as a competitive or mechanism-based inhibitor of the following human P450 enzymes: CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5 or CYP4A9/11-2.<br />Elimination<br />The plasma elimination half-life is approximately 6-10 hours in healthy subjects and patients with epilepsy. When given twice daily at 12-hourly intervals, rufinamide accumulates to the extent predicted by its terminal half-life, indicating that the pharmacokinetics of rufinamide are time-independent (i.e. no autoinduction of metabolism).<br />In a radiotracer study in three healthy volunteers, the parent compound (rufinamide) was the main radioactive component in plasma, representing about 80% of the total radioactivity, and the metabolite CGP 47292 constituting only about 15%. Renal excretion was the predominant route of elimination for active substance related material, accounting for 84.7% of the dose.<br />Linearity/non-linearity<br />The bioavailability of rufinamide is dependent on dose. As dose increases, the bioavailability decreases.<br />Pharmacokinetics in special patient groups<br />Sex<br />Population pharmacokinetic modelling has been used to evaluate the influence of sex on the pharmacokinetics of rufinamide. Such evaluations indicate that sex does not affect the pharmacokinetics of rufinamide to a clinically relevant extent.<br />Renal impairment&nbsp;</p><p>The pharmacokinetics of a single 400 mg dose of rufinamide were not altered in subjects with chronic and severe renal failure compared to healthy volunteers. However, plasma levels were reduced by approximately 30% when haemodialysis was applied after administration of rufinamide, suggesting that this may be a useful procedure in case of overdose (see sections 4.2 and 4.9).<br />Hepatic impairment<br />No studies have been performed in patients with hepatic impairment and therefore rufinamide should not be administered to patients with severe hepatic impairment (see section 4.2).<br />Elderly<br />A pharmacokinetic study in older healthy volunteers did not show a significant difference in pharmacokinetic parameters compared with younger adults.<br />Children (1-12 years)<br />Children generally have lower clearance of rufinamide than adults, and this difference is related to body size with rufinamide clearance increasing with body weight.<br />A recent population PK analysis of rufinamide on data pooled from 139 subjects (115 LGS patients and 24 healthy subjects), including 83 paediatric LGS patients (10 patients aged 1 to &lt; 2 years, 14 patients aged 2 to &lt; 4 years, 14 patients aged 4 to &lt; 8 years, 21 patients aged 8 to &lt; 12 years and 24 patients aged 12 to &lt; 18 years) indicated that when rufinamide is dosed on a mg/kg/day basis in LGS subjects aged 1 to &lt; 4 years, comparable exposure to that in LGS patients aged &ge; 4 years, in which efficacy has been demostrated, is achieved.<br />Studies in new-born infants or infants and toddlers under 1 year of age have not been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Conventional safety pharmacology studies revealed no special hazards at clinically relevant doses.<br />Toxicities observed in dogs at levels similar to human exposure at the maximum recommended dose were liver changes, including bile thrombi, cholestasis and liver enzyme elevations thought to be related to increased bile secretion in this species. No evidence of an associated risk was identified in the rat and monkey repeat dose toxicity studies.&nbsp;In reproductive and developmental toxicity studies, there were reductions in foetal growth and survival, and some stillbirths secondary to maternal toxicity. However, no effects on morphology and function, including learning or memory, were observed in the offspring. Rufinamide was not teratogenic in mice, rats or rabbits.<br />The toxicity profile of rufinamide in juvenile animals was similar to that in adult animals. Decreased body weight gain was observed in both juvenile and adult rats and dogs. Mild toxicity in the liver was observed in juvenile as well as in adult animals at exposure levels lower than or similar to those reached in patients. Reversibility of all findings was demonstrated after stopping treatment.<br />Rufinamide was not genotoxic and had no carcinogenic potential. An adverse effect not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to human use, was myelofibrosis of the bone marrow in the mouse carcinogenicity study. Benign bone neoplasms (osteomas) and hyperostosis seen in mice were considered a result of the activation of a mouse specific virus by fluoride ions released during the oxidative metabolism of rufinamide.<br />Regarding the immunotoxic potential, small thymus and thymic involution were observed in dogs in a 13-week study with significant response at the high dose in male. In the 13-week study, female bone marrow and lymphoid changes are reported at the high dose with a weak incidence. In rats, decreased cellularity of the bone marrow and thymic atrophy were observed only in the carcinogenicity study.<br />Environmental Risk Assessment (ERA):<br />Environmental risk assessment studies have shown that rufinamide is very persistent in the environment (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rufinamide Oral Suspension 40mg/mL<br />The other ingredients are: Microcrystalline cellulose and Carboxymethylcellulose sodium, Simethicone Emulsion 30%, Poloxamer, Hydroxyethyl cellulose, Noncrystallizing Sorbitol solution 70%, Potassium Sorbate, Propylene glycol, Methylparaben, Propylparaben, Anhydrous&nbsp;Citric Acid, Orange 051941A and Purified Water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
In-Use Shelf life
Use within 90 days of first opening the bottle, then discard any remainder.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30⁰C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pack Size: 460 mL in Amber PET Bottle Pack.<br />Container: Amber color PET bottle 16 oz with 24 mm Neck<br />Closure: Child resistant plastic caps with Expanded PE wad, 24 mm<br />Oral Dosing Syringe: 20 mL Polypropylene Oral Dosing Syringe With Adapter (2 no&rsquo;s Syringes and 1 no. Adapter) (1 to 20mL Markings)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company,
Aljameah Street, Malaz quarter, Riyadh 11441,
Saudi Arabia
Tel: +966 11 477 2215
Manufacture: Hetero Lab Unit III, Hyderabad, India
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October - 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>